Literature DB >> 16361730

Narrow-band UVB treatment of vitiligo in Chinese.

Guan-Yu Chen1, M Ming-Long Hsu, Han-Kuo Tai, Tzu-Chieh Chou, Ching-Liang Tseng, Ho-Yuan Chang, Cheng-Che Eric Lan, Hamm-Ming Sheu.   

Abstract

Narrow-band ultraviolet B (NBUVB) phototherapy has recently been reported to be an effective and safe treatment modality for vitiligo. In the present report, we evaluated the efficacy and safety of NBUVB therapy for vitiligo in Chinese patients. Seventy-two vitiligo patients treated from 2000 to 2003, were included retrospectively (male: female=33:39, mean age: 38.5). Among them, 61 were non-segmental type and 11 the segmental type. Treatments were given two to three times a week for a maximum period of one year with an initial dose of 0.2 J/cm2 and a 0-20% increment each session (mean accumulation dose: 155.3 J/cm2). Computer image analysis by Supervise classification was used to estimate the area of vitiligo involvement before and after treatment. An excellent response (75-100% area of repigmentation) was obtained in 9 patients (12.5%) and a good response (50-75%) in 24 (33.3%), a moderate response (25-50%) in 20 (27.8%), and a poor response (0-25%) in 19 (26.4%). In summary, 45.8% of our patients had more than 50% repigmentation. Burns were a side effect in 5 patients (7%) and transient erythema with itching or xerosis was noted in 5 patients (7%). These results indicate that NBUVB phototherapy is an effective and safe treatment choice for generalized vitiligo.

Entities:  

Mesh:

Year:  2005        PMID: 16361730     DOI: 10.1111/j.1346-8138.2005.tb00847.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  2 in total

1.  A case of vitiligo vulgaris showing a pronounced improvement after treatment for myasthenia gravis.

Authors:  Kiyotaka Nakamagoe; Jun-Ichi Furuta; Ayako Shioya; Akira Tamaoka
Journal:  BMJ Case Rep       Date:  2009-12-09

2.  Evaluation of skin expression profiles of patients with vitiligo treated with narrow-band UVB therapy by targeted RNA-seq.

Authors:  Jorge Ocampo-Candiani; Mauricio Salinas-Santander; Victor Trevino; Rocio Ortiz-López; Jorge Ocampo-Garza; Celia Nohemi Sanchez-Dominguez
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.